logo
logo
Definitive Healthcare Corp.

Definitive Healthcare Corp.

NASDAQ•DH
CEO: Mr. Kevin D. Coop
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2021-09-15
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
連絡先情報
492 Old Connecticut Path, Suite 401, Framingham, MA, 01701, United States
508-720-4224
www.definitivehc.com
時価総額
$159.09M
PER (TTM)
-0.8
53.6
配当利回り
--
52週高値
$5.68
52週安値
$1.52
52週レンジ
0%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$60.05M-4.23%
直近4四半期の推移

EPS

-$0.14-87.50%
直近4四半期の推移

フリーCF

$13.41M-28.18%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Loss Narrows Significantly Net loss attributable to DH Corp improved to $(129.6M) from $(354.0M), driven by no goodwill impairment charge in 2025.
Operating Cash Flow Stable Net cash provided by operating activities was $51.1M for nine months 2025, slightly up from $50.1M in the prior year.
Asset Base Reduced Post-Impairment Total assets fell to $755.5M from $1.09B, reflecting the non-cash goodwill impairment recorded in Q1 2025.
Share Repurchases Continue Company repurchased $49.5M of Class A common stock during the nine months ended September 30, 2025.

リスク要因

Revenue Growth Expected Negative Revenue decreased 5% to $180.0M (9M 2025); expect negative revenue growth rate for fiscal 2025 relative to 2024.
Customer Churn Heightened Macroeconomic factors cause deal cycles to lengthen and heightened customer churn, particularly impacting smaller customers.
Goodwill Impairment Risk Remains Reporting unit remains at risk for future goodwill impairments if market capitalization experiences continued decline.
Executive Leadership Changes Recent executive transitions, including CFO departure and COO role elimination, introduce organizational uncertainty.

見通し

Focus on Enterprise Customers Go-to-market strategy remains focused on acquiring and expanding Enterprise Customers generating over $100,000 in ARR.
Platform Innovation Investment Continued significant investment planned for engineering and R&D to enhance platform capabilities and expand use cases.
Liquidity Position Strong Anticipate current cash of $108.3M and $49.7M available credit to meet liquidity needs for at least twelve months.
Data Source Risk Mitigation Working to renegotiate select existing agreements and add new data sources to mitigate risks from data source disruption.

同業比較

売上高 (TTM)

Owens & Minor, Inc.OMI
$6.71B
+44.5%
TruBridge, Inc.TBRG
$349.88M
+3.1%
Definitive Healthcare Corp.DH
$242.28M
-5.3%

粗利益率 (最新四半期)

Lyell Immunopharma, Inc.LYEL
100.0%
+0.0pp
Editas Medicine, Inc.EDIT
100.0%
+2621.3pp
Definitive Healthcare Corp.DH
84.9%
+6.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
LYEL$539.17M-1.4-96.7%10.9%
SOPH$322.27M-4.3-93.9%38.8%
NRC$290.69M24.158.5%58.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.2%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.06
|
売上高:$59.57M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $60.05M-4.2%
    |
    EPS: $-0.14-87.5%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $60.75M-4.7%
    |
    EPS: $-0.07-96.1%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $59.19M-6.8%
    |
    EPS: $-0.95+1071.4%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $252.20M+0.3%
    |
    EPS: $-3.54-97.8%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $62.70M-4.0%
    |
    EPS: $-1.12-25.3%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月5日|
    売上高: $63.74M+4.6%
    |
    EPS: $-1.81+2262.9%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $63.48M+7.2%
    |
    EPS: $-0.08-42.1%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $251.42M+12.9%
    |
    EPS: $-1.79-2407.0%
    予想を下回る